Physician Biosimilar Testimonials

Thursday February 27, 2020

“It is absolutely safe for a patient to switch from a biologic to a biosimilar because their qualities are similar. They work for the same kind of condition and their purity is the same as they have been tested for the same kinds of conditions”

“We have studies from all over the world and we find that patients have the same kind of benefits whether they are on the original biologic or the biosimilar.”

– Sameer Awsare, M.D., Associate Executive Director, The Permanente Medical Group

sameer awsare headshot

Dr. Awsare works closely with patients who are directly impacted by the promise of biosimilars. His knowledge of the industry and work with Kaiser Permanente – a leader driving the adoption of biosimilars – gives him a unique perspective on this important issue.

scott gottlieb headshot

“Biosimilars are growing their market share and leading to meaningful price erosion over time; with the more recent biosimilar launches showing a lot of success – reflecting perhaps the growing market sophistication of the biosimilar companies.”

– Scott Gottlieb, M.D., Former FDA Commissioner

“These medicines are pretty amazing…we need patients to be able to get the medicines they need.”

– Sarah Yim, M.D., Acting Director OTTB

sarah yim headshot
gary lyman headshot

“To facilitate the development of biosimilars, the FDA created a more expedited process for the approval of biosimilars a few years ago, in which emphasis is put on the molecular characteristics, structure, and the product’s biologic behavior in the patient. This should demonstrate that the biosimilar is highly similar to the original product without the additional cost of large, randomized, phase III trials.”

– Gary H. Lyman, M.D., MPH, medical oncologist, Fred Hutchinson Cancer Research Center

“…It’s important to note that a biosimilar drug is so similar, to the point where it has the same clinical effect. The same effectiveness and the same safety profile as the originator biologic.”

“Every biologic drug will vary from one to the next. That’s completely expected; however, every biological drug – again, originator or biosimilar – has to be manufactured to stay within very specific ranges for each parameter that’s being measured. That itself is linked to the safety and effectiveness of the drug. By staying within these pre-defined limits, and as monitored by the company and then the data reviewed by the FDA, patients can be assured that by taking a biosimilar the have the same outcomes as with the originator biologic.”

“It’s important to realize that interchangeability is a regulatory designation. It’s actually optional, because physicians – even without this interchangeability designation – have the ability to prescribe whatever product they want, including a biosimilar in place of a reference biologic.”

– Hillel Cohen, Ph.D., Executive Director, Scientific Affairs, Sandoz

hillel cohen headshot

Hillel has held numerous high-profile industry roles focused on creating a robust biosimilars market for patients, including as a member of the Biosimilars Council Education Committee. In 2015, Hillel led the efforts for the first-ever presentation of a biosimilar to a U.S. advisory committee, following Sandoz submitting a Biologics License Application for Zarxio (filgrastim-sndz).

anna abram headshot

“Patients and providers should know biosimilars are safe and effective…provide more treatment options…potentially lower healthcare costs.”

– Anna Abram, Deputy Commissioner for Policy, Legislation, and International Affairs, FDA

“The biosimilar advances have allowed us to not only continue to bring great clinical care, but to lower the cost thereof.”

–Tracy L. Bahl, CEO of OneOncology

tracy bahl headshot

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.